Table 3.
Main modeling outcomes
| Treatment naïves population | ||||
|---|---|---|---|---|
| PR | Boceprevir + PR | SOF/RBV | SOF/SMV | |
| Clinical outcomes | ||||
| SVR (24 weeks after tx) | 46.62 % | 58.58 % | 47.37 % | 93.31 % |
| Decompensated cirrhosis | 11.88 % | 10.07 % | 10.64 % | 1.73 % |
| Hepatocellular carcinoma | 5.65 % | 4.97 % | 5.30 % | 2.15 % |
| Liver Transplantation | 1.42 % | 1.22 % | 1.27 % | 0.26 % |
| Liver related death | 13.52 % | 11.71 % | 12.22 % | 3.22 % |
| Costs | ||||
| Total Costs | 35,358.93 € | 52,679.70 € | 127,891.69 € | 106,868.76 € |
| Drug costs | 21,842.68 € | 41,842.96 € | 117,578.96 € | 103,641.74 € |
| Of which PI | - € | 23,606.10 € | 113,152.56 € | 102,535.14 € |
| Of which (P)R | 21,842.68 € | 18,236.86 € | 4,426.40 € | 1,106.60 € |
| Pre-treatment evaluation | 170.99 € | 85.00 € | 85.00 € | 85.00 € |
| Monitoring costs | 1,287.97 € | 1,207.16 € | 1,084.00 € | 878.97 € |
| Adverse event cost | 450.07 € | 923.49 € | 7.00 € | 162.53 € |
| SVR, F0-F2 | 50.75 € | 66.06 € | 46.86 € | 94.11 € |
| SVR, F3 | 25.34 € | 13.18 € | 15.16 € | 28.64 € |
| SVR, F4 | 63.40 € | 27.77 € | 31.94 € | 60.34 € |
| F0-F2 | 703.42 € | 491.51 € | 778.50 € | 72.15 € |
| F3 | 2,881.21 € | 1,109.77 € | 1,268.17 € | 185.75 € |
| F4 | 1,258.16 € | 1,082.28 € | 1,105.84 € | 187.26 € |
| DCC | 2,963.85 € | 2,595.90 € | 2,614.33 € | 450.92 € |
| HCC | 1,459.78 € | 1,307.52 € | 1,348.52 € | 588.77 € |
| LT | 1,133.50 € | 987.14 € | 998.37 € | 219.54 € |
| pLT | 1,067.81 € | 939.97 € | 929.03 € | 213.03 € |
PR PegInterferon and Ribavirin, SOF Sofosbuvir, SMV Simeprevir, SVR sustained virologic response, PI protease inhibitor, fibrosis states F0-F4 according to METAVIR, DCC decompensated cirrhosis, HCC hepatocellular carcinoma, LT, first year after liver transplant, pLT further years after liver transplant